<--- Back to Details
First PageDocument Content
Gynaecological cancer / Anatomical pathology / Lung cancer / Carcinoma / Squamous-cell carcinoma / Melanoma / Metastasis / Keratoacanthoma / Dermatofibrosarcoma protuberans / Medicine / Oncology / Gastrointestinal cancer
Date: 2014-10-30 19:05:52
Gynaecological cancer
Anatomical pathology
Lung cancer
Carcinoma
Squamous-cell carcinoma
Melanoma
Metastasis
Keratoacanthoma
Dermatofibrosarcoma protuberans
Medicine
Oncology
Gastrointestinal cancer

CLINICAL Ranjan Gupta Cutaneous manifestation of visceral malignancy:

Add to Reading List

Source URL: www.racgp.org.au

Download Document from Source Website

File Size: 67,35 KB

Share Document on Facebook

Similar Documents

#4503 A Small Molecule Glycomimetic Antagonist of E-selectin (GMIPrevents Pancreatic Tumor Metastasis and Offers Improved Efficacy of Chemotherapy Maria M. Steele1, BS, Prakash Radhakrishnan1, PhD, John L. Magnani

DocID: 1vkKU - View Document

Quantitative image-based phenotypes for cancer metastasis systems biology Joel S. Bader, Ph.D. Professor, Biomedical Engineering Johns Hopkins University

DocID: 1vd8y - View Document

A  small  molecule  glycomime.c  antagonist   of  E-­‐selec.n  and  CXCR4  (GMI-­‐1359)   delays  pancrea.c  tumor  metastasis  and   significantly  alters  the

DocID: 1uubq - View Document

Why we focus on Metastasis & Invasion Around 90% of cancer deaths are attributable to invasion and metastasis. Metastasis is the spread of disease from one organ or part to another not directly connected with the primary

DocID: 1sjoH - View Document

Nota de Prensa LA FDA APRUEBA DENOSUMAB PARA LA PREVENCIÓN DE EVENTOS ESQUELÉTICOS EN PACIENTES CON METÁSTASIS ÓSEAS DE TUMORES SÓLIDOS BARCELONA. (nov. 19, 2010) – La FDA ha aprobado denosumab, el primer y

DocID: 1s5nh - View Document